List view / Grid view
26 January 2012 | By Biogen Idec
Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS...
26 January 2012 | By Amgen
Amgen and Micromet, Inc. announced that the companies have entered into a definitive merger agreement...
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Antonella Mancuso has been promoted to President, Global Commercial Operations and Chief Manufacturing Officer, responsible for Patheon's global commercial manufacturing operations . Ms. Mancuso will assume responsibility for all of…
25 January 2012 | By Merck
The FDA has approved an updated label for VYTORIN® (ezetimibe/simvastatin)...
25 January 2012 | By Roche
Roche announced that it is proposing to acquire all outstanding shares of Illumina, Inc...
24 January 2012 | By Sanofi
The FDA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme® (agalsidase beta)...
24 January 2012 | By Eli Lilly and Company
Elanco, announced that Lilly has signed an agreement to acquire ChemGen Corp., a privately held bioscience company...
24 January 2012 | By Novo Nordisk
Novo Nordisk announced that the company will establish a type 1 diabetes R&D center in Seattle, US...
24 January 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that its Board of Directors has elected Gerald L. Storch to the Board...
23 January 2012 | By Roche
Establishment of a program to improve basic cancer care in Ethiopia...
20 January 2012 | By Novartis
If approved, Signifor would be the first approved medication targeting Cushing's disease...
20 January 2012 | By Biogen Idec and Elan Corporation, plc
The U.S. FDA has approved a product label change for TYSABRI...
20 January 2012 | By Novartis
Update of the Glivec® (imatinib)* label...
19 January 2012 | By Merck
Merck announced that it has entered into an agreement to resolve all claims related to Vioxx® in Canada...
